Moreover, we discuss potential mechanisms of impaired TKI response in CML, in particular genomics of BCR-ABL1, the impact of variants in cytochrome P450 enzymes and drug transporters, as well as alternative mechanisms of resistance. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.